Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) a developer of oral drug delivery systems announced that it will announce the results of its Phase 2a clinical trial for the company’s ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes on January 30, 2014. Oramed CEO Nadav Kidron will present the findings at an investor conference taking place at the Tel Aviv Stock Exchange in Tel Aviv, Israel. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) stock opened at $20.86 in last session, and closed at $24.38, while the day range of stock is $20.80 – $25.92. The stock showed a positive weekly performance of 5.63%.
Checking the TheTechTrader.com percent-gain leaderboard, low-priced biotech ProPhase Labs, Inc. (NASDAQ:PRPH) popped 49 cents to 2.25, or 28%, on 1.7 million shares, after trading as high as 2.98 earlier yesterday. ProPhase Labs, Inc. (NASDAQ:PRPH) stock opened at $2.10, in last session and closed at $2.25, by gaining 27.84%. The 52 week range of the stock is $1.35 – $2.98. Company’s market capitalization is $35.74 million.
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares soared by 267 per cent to end the year at 77¢. It is yet to apply for any regulatory approvals but already has a market capitalisation of $299 million. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) stock advanced 7.79% and finished the last session at $9.69. The EPS of the stock remained -0.20. Company’s market capitalization is $394.78 million.
IMRIS Inc (NASDAQ:IMRS) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Monday, StockRatingsNetwork.com reports. IMRIS Inc (NASDAQ:IMRS) stock opened the session at $1.99, and closed the session at $2.06. The 52 week range of the stock remained $1.16 – $4.31 and the day range was $1.96 – $2.18.